Proteomic profiling in schizophrenia: enabling stratification for more effective treatment
1 Department of Chemical Engineering and Biotechnology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QT, UK
2 Max Planck Institute of Psychiatry, Proteomics and Biomarkers, Kraepelinstr. 2-10 80804, Munich, Germany
3 Department of Psychiatry, Ludwig-Maximilians-University (LMU), Nussbaumstr. 7, 80336, Munich, Germany
4 Laboratório de Neurociências (LIM-27), Instituto de Psiquiatria, Faculdade de Medicina, Universidade de São Paulo, CP 8091 05403-010 São Paulo - SP - Brasil
5 Department of Neuroscience, Erasmus Medical Centre, NL-3000 CA Rotterdam, The Netherlands
Genome Medicine 2013, 5:25 doi:10.1186/gm429Published: 26 March 2013
Schizophrenia is a heterogeneous psychiatric disorder characterized by an array of clinical manifestations. Although the best known manifestations include serious effects on mood and behavior, patients can also display co-morbidities, including immune system or metabolic abnormalities. Thorough characterization of these conditions using proteomic profiling methods has increased our knowledge of these molecular differences and has helped to unravel the complexity and heterogeneity of this debilitating condition. This could lead to patient stratification through characterization of biochemically different subtypes of the disease. In addition, proteomic methods have recently been used for molecular characterization of the mechanism of action of antipsychotic medications in both preclinical models and patients. This has resulted in identification of molecular panels that show some promise for prediction of response or for monitoring treatment outcome. This review describes how proteomic profiling methods can impact the future of schizophrenia diagnosis and therapeutics, and facilitate personalized medicine approaches for more effective treatment management of schizophrenia patients.